Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency.
Rotary Bone Marrow Research Laboratory, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Matthew P
MP
McCormack
Terence H
TH
Rabbitts
D048868:Adaptor Proteins, Signal Transducing; D000818:Animals; D004268:DNA-Binding Proteins / Q000235:genetics*; D005786:Gene Expression Regulation; D015973:Gene Expression Regulation, Leukemic; D040181:Genetic Diseases, X-Linked / Q000235:genetics / Q000628:therapy; D015316:Genetic Therapy / Q000009:adverse effects*; D006801:Humans; D060588:LIM Domain Proteins; D015458:Leukemia, T-Cell / Q000235:genetics; D008667:Metalloproteins / Q000235:genetics*; D009857:Oncogenes; D011518:Proto-Oncogene Proteins; D015375:Receptors, Interleukin-2 / Q000235:genetics; D012190:Retroviridae / Q000235:genetics / Q000502:physiology; D016511:Severe Combined Immunodeficiency / Q000235:genetics / Q000628:therapy*; D013601:T-Lymphocytes; D014178:Translocation, Genetic; D014775:Virus Activation
D048868:Adaptor Proteins, Signal Transducing; D004268:DNA-Binding Proteins; D060588:LIM Domain Proteins; C085117:LMO2 protein, human; D008667:Metalloproteins; D011518:Proto-Oncogene Proteins; D015375:Receptors, Interleukin-2